PMID- 17317585
OWN - NLM
STAT- MEDLINE
DCOM- 20070614
LR  - 20071115
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 13
IP  - 3
DP  - 2007 Mar
TI  - Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on 
      clinical outcome in leukemia patients undergoing transplantation with 
      T-cell-replete marrow from an unrelated donor.
PG  - 315-28
AB  - The responsible human leukocyte antigen (HLA) locus and the role of killer 
      immunoglobulin-like receptor (KIR) ligand matching on transplantation outcome 
      were simultaneously identified by multivariate analysis in 1790 patients with 
      leukemia who underwent transplantation with T-cell-replete marrow from an 
      unrelated donor (UR-BMT) through the Japan Marrow Donor Program. The 
      graft-versus-leukemia (GVL) effect depended on leukemia cell type. HLA-C mismatch 
      reduced the relapse rate in acute lymphoblastic leukemia (ALL) (hazard ratio [HR] 
      = 0.47; P = .003), and HLA-DPB1 mismatch reduced it in chronic myeloid leukemia 
      (CML) (HR = 0.35; P < .001). In contrast, KIR2DL ligand mismatch in the 
      graft-versus-host (GVH) direction (KIR-L-MM-G) increased in ALL (HR = 2.55; P = 
      .017). An increased rejection rate was observed in KIR2DL ligand mismatch in the 
      host-versus-graft direction (HR = 4.39; P = .012). Acute GVH disease (GVHD) was 
      increased not only in the mismatch of HLA-A, -B, -C, and -DPB1, but also in 
      KIR-L-MM-G. As a whole, the mismatch of HLA-A, -B, and -DQB1 locus and KIR-L-MM-G 
      resulted in increased mortality. In conclusion, not only the mismatch of HLA-C 
      and -DPB1, but also KIR-L-MM-G affected leukemia relapse, which should be 
      considered based on leukemia cell type. Furthermore, KIR-L-MM induced adverse 
      effects on acute GVHD (aGVHD) and rejection, and brought no survival benefits to 
      patients with T-cell-replete UR-BMT.
FAU - Morishima, Yasuo
AU  - Morishima Y
AD  - Aichi Cancer Center Hospital, Department of Hematology and Cell Therapy, Nagoya, 
      Japan. ymorisim@aichi-cc.jp <ymorisim@aichi-cc.jp>
FAU - Yabe, Toshio
AU  - Yabe T
FAU - Matsuo, Keitaro
AU  - Matsuo K
FAU - Kashiwase, Koichi
AU  - Kashiwase K
FAU - Inoko, Hidetoshi
AU  - Inoko H
FAU - Saji, Hiroh
AU  - Saji H
FAU - Yamamoto, Ken
AU  - Yamamoto K
FAU - Maruya, Etsuko
AU  - Maruya E
FAU - Akatsuka, Yoshiki
AU  - Akatsuka Y
FAU - Onizuka, Makoto
AU  - Onizuka M
FAU - Sakamaki, Hisashi
AU  - Sakamaki H
FAU - Sao, Hiroshi
AU  - Sao H
FAU - Ogawa, Seishi
AU  - Ogawa S
FAU - Kato, Shunichi
AU  - Kato S
FAU - Juji, Takeo
AU  - Juji T
FAU - Sasazuki, Takehiko
AU  - Sasazuki T
FAU - Kodera, Yoshihisa
AU  - Kodera Y
CN  - Japan Marrow Donor Program
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Transplantation/*methods
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Graft vs Host Disease/immunology
MH  - Graft vs Leukemia Effect/immunology
MH  - HLA Antigens/*immunology
MH  - HLA-C Antigens
MH  - HLA-DP Antigens
MH  - Histocompatibility/*immunology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Leukemia/*therapy
MH  - Ligands
MH  - Lymphocyte Depletion
MH  - Male
MH  - Middle Aged
MH  - Receptors, Immunologic/*immunology
MH  - Receptors, KIR
MH  - Tissue Donors
MH  - Treatment Outcome
EDAT- 2007/02/24 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/02/24 09:00
PHST- 2006/06/04 00:00 [received]
PHST- 2006/10/26 00:00 [accepted]
PHST- 2007/02/24 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/02/24 09:00 [entrez]
AID - S1083-8791(06)00749-X [pii]
AID - 10.1016/j.bbmt.2006.10.027 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2007 Mar;13(3):315-28. doi: 
      10.1016/j.bbmt.2006.10.027.